Breaking News Instant updates and real-time market news.

BMRN

BioMarin

$88.30

-0.2 (-0.23%)

20:41
05/24/18
05/24
20:41
05/24/18
20:41

BioMarin approval of Palynziq is good news, says Piper Jaffray

Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $114 price target on BioMarin after the FDA approval of its Palynziq treatment of PKU a day before PDUFA. The analyst adds that while the approval was expected, better labeling and higher pricing for the drug suggest potential upside for the stock price. Raymond notes that this approval has been the "lynchpin" to Biomarin's transformation to "sustainably high EPS", expecting shares to move "measurably" higher in the coming quarters.

  • 25

    May

  • 12

    Sep

BMRN BioMarin
$88.30

-0.2 (-0.23%)

05/22/18
EVER
05/22/18
NO CHANGE
EVER
BioMarin hemophilia A data remain 'intriguing,' says Evercore ISI
Evercore ISI analyst Josh Schimmer attributes the weakness in shares of BioMarin this morning to Factor VIII levels waning somewhat from one year to two years in the updated data from the Phase 1/2 study of Valrox. The company, however, remains optimistic that levels have stabilized based on preclinical models, Schimmer tells investors in a research note. He believes BioMarin's hemophilia A data remain "intriguing," but that long-term expression levels need to be watched and better understood. Schimmer points out Valrox is not a meaningful driver of his Outperform investment thesis BioMarin, which centers on upward revisions to outer-year estimates driven by pegvaliase.
05/22/18
PIPR
05/22/18
NO CHANGE
PIPR
Overweight
BioMarin weakness on valrox data a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said following the presentation of longer-term data at the World Federation of Hemophilia that valrox remains "best-in-class" in terms of hemophilia A gene therapy and he believes the weakness in shares of BioMarin seems misplaced. While mean and median F8 levels did moderate from the 78-week data, management is confident based on preclinical experience that F8 activity is approaching a plateau, said Raymond. In terms of safety, prior concerns over F8 overexpression "just evaporated" with no F8 activity above the upper limit of normal in 6E13 vg/kg dose patients, added Raymond, who calls the weakness a buying opportunity and keeps an Overweight rating on BioMarin shares.
05/22/18
SBSH
05/22/18
NO CHANGE
SBSH
Neutral
Spark Therapeutics should not be higher on BioMarin data, says Citi
Citi analyst Mohit Bansal says shares of Spark Therapeutics (ONCE) should not trading high on BioMarin's (BMRN) updated hemophilia A data. The tapering of factor levels in BioMarin's data from year one to year two is not a positive for Spark as it is making investors concerned if Spark factor levels would also taper in long term, Bansal tells investors in a research note. Further, BioMarin's decision to run a controlled superiority trial could make the bar higher for Spark as the company may also have to do a similar trial to be competitive, the analyst adds. He has a Neutral rating on Spark shares. The stock in late morning trading is up $1.03 to $74.12.
05/22/18
JEFF
05/22/18
NO CHANGE
Target $116
JEFF
Buy
BioMarin 'raised efficacy bar' with valrox Phase 3 modification, says Jefferies
Jefferies analyst Eun Yang said BioMarin's updated Phase 1/2 data for valrox for hemophilia A showed a decline in F8 levels at two years compared to 1.5 years, but she typified the results as showing "continuing strong efficacy" and noted the company seems confident of entering a stable expression phase. The company also announced a modification to its ongoing GENEr8-1 Phase 3 trial to show superiority versus the current standard of care, which raises the bar for efficacy but also for potential clinical risks, though the change supports the company's commercial rationale, said Yang, who keeps her Buy rating and $116 price target on BioMarin shares.

TODAY'S FREE FLY STORIES

PSDO

Presidio

$16.38

-0.46 (-2.73%)

09:12
09/18/18
09/18
09:12
09/18/18
09:12
Syndicate
Presidio 3M share Spot Secondary priced at $15.40 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

CBZ

CBIZ

$23.70

0.1 (0.42%)

09:11
09/18/18
09/18
09:11
09/18/18
09:11
Initiation
CBIZ initiated  »

William Blair calls CBIZ…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRV

ContraVir Pharmaceuticals

$0.72

-0.0098 (-1.35%)

09:11
09/18/18
09/18
09:11
09/18/18
09:11
Hot Stocks
ContraVir Pharmaceuticals CRV431 study meets primary endpoints »

ContraVir Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$217.86

-5.98 (-2.67%)

09:10
09/18/18
09/18
09:10
09/18/18
09:10
Periodicals
Apple CEO Tim Cook confident on U.S., China trade discussions, Reuters reports »

Apple CEO Tim Cook, whose…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$83.25

-0.24 (-0.29%)

09:10
09/18/18
09/18
09:10
09/18/18
09:10
Recommendations
Nike analyst commentary  »

Nike positioned for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

  • 25

    Sep

RLMD

Relmada Therapeutics

$0.00

(0.00%)

09:09
09/18/18
09/18
09:09
09/18/18
09:09
Hot Stocks
Relmada says top-line data from Phase 2 MDD study expected in first half of 2019 »

Relmada Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$12.71

0.02 (0.16%)

09:09
09/18/18
09/18
09:09
09/18/18
09:09
Hot Stocks
GE Transportation to supply five diesel-electric locomotives to Korfez Ulastirma »

GE Transportation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

PERY

Perry Ellis

$27.47

-0.02 (-0.07%)

09:08
09/18/18
09/18
09:08
09/18/18
09:08
Hot Stocks
Perry Ellis, PGA Tour announce extension of partnership »

Perry Ellis and the PGA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

TTEK

Tetra Tech

$71.00

-0.7 (-0.98%)

09:08
09/18/18
09/18
09:08
09/18/18
09:08
Hot Stocks
Tetra Tech awarded $21M contract by USAID »

Tetra Tech announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NXEO

Nexeo Solutions

$10.01

-0.04 (-0.40%)

, UNVR

Univar

$27.67

0.29 (1.06%)

09:08
09/18/18
09/18
09:08
09/18/18
09:08
Downgrade
Nexeo Solutions, Univar rating change  »

Nexeo Solutions…

NXEO

Nexeo Solutions

$10.01

-0.04 (-0.40%)

UNVR

Univar

$27.67

0.29 (1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BXP

Boston Properties

$127.02

1.06 (0.84%)

09:06
09/18/18
09/18
09:06
09/18/18
09:06
Hot Stocks
Boston Properties raises quarterly dividend 18.75% to 95c per share »

Boston Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

ROX

Castle Brands

$1.01

0.0268 (2.73%)

09:06
09/18/18
09/18
09:06
09/18/18
09:06
Recommendations
Castle Brands analyst commentary  »

Castle Brands pullback…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

CASY

Casey's General Stores

$125.30

-0.76 (-0.60%)

09:06
09/18/18
09/18
09:06
09/18/18
09:06
Upgrade
Casey's General Stores rating change  »

Casey's General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

FBC

Flagstar Bancorp

$31.13

0.125 (0.40%)

09:06
09/18/18
09/18
09:06
09/18/18
09:06
Conference/Events
Flagstar Bancorp management to meet with Piper Jaffery »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 05

    Dec

  • 06

    Dec

SSNC

SS&C

$55.62

-1.89 (-3.29%)

09:04
09/18/18
09/18
09:04
09/18/18
09:04
Hot Stocks
SS&C announces Gateway Health extended relationship with DST Health Solutions »

SS&C Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

  • 20

    Sep

  • 03

    Oct

ORCL

Oracle

$49.19

-0.06 (-0.12%)

09:02
09/18/18
09/18
09:02
09/18/18
09:02
Technical Analysis
Technical Take: Oracle falls after earnings »

In early trading the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

GIGM

GigaMedia

$3.10

0.08 (2.65%)

09:02
09/18/18
09/18
09:02
09/18/18
09:02
Hot Stocks
GigaMedia's CEO acquires 69,967 shares of GigaMedia stock »

GigaMedia announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$289.41

-1.53 (-0.53%)

, SPX

S&P 500

$0.00

(0.00%)

09:02
09/18/18
09/18
09:02
09/18/18
09:02
General news
Trump warns on 'great and fast economic retaliation' if China targets farmers »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$289.41

-1.53 (-0.53%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$49.19

-0.06 (-0.12%)

09:01
09/18/18
09/18
09:01
09/18/18
09:01
Recommendations
Oracle analyst commentary  »

Oracle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

BRC

Brady

$45.35

-1.05 (-2.26%)

09:00
09/18/18
09/18
09:00
09/18/18
09:00
Downgrade
Brady rating change  »

Brady downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGIX

Cancer Genetics

$1.07

0.025 (2.39%)

09:00
09/18/18
09/18
09:00
09/18/18
09:00
Hot Stocks
Breaking Hot Stocks news story on Cancer Genetics »

Cancer Genetics trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATHN

Athenahealth

$143.26

-0.895 (-0.62%)

08:59
09/18/18
09/18
08:59
09/18/18
08:59
Technical Analysis
Technical Take: Athenahealth falls after word Elliott backing away from $160 bid »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$294.78

-0.33 (-0.11%)

, AUDVF

Audi AG

$0.00

(0.00%)

08:58
09/18/18
09/18
08:58
09/18/18
08:58
Recommendations
Tesla, Audi AG analyst commentary  »

Audi e-tron underscores…

TSLA

Tesla

$294.78

-0.33 (-0.11%)

AUDVF

Audi AG

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 29

    Oct

WRK

WestRock

$55.94

0.11 (0.20%)

08:57
09/18/18
09/18
08:57
09/18/18
08:57
Hot Stocks
WestRock says didn't suffer material physical damage to facilities in hurricane »

WestRock provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

FTV

Fortive

$87.14

0.165 (0.19%)

, SNAP

Snap

$9.17

-0.12 (-1.29%)

08:55
09/18/18
09/18
08:55
09/18/18
08:55
Options
Notable open interest changes for September 18th »

Monday's total…

FTV

Fortive

$87.14

0.165 (0.19%)

SNAP

Snap

$9.17

-0.12 (-1.29%)

AMD

AMD

$32.44

-0.27 (-0.83%)

GE

General Electric

$12.71

0.02 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 25

    Sep

  • 27

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.